Recently identified biomarkers that promote lymph node metastasis in head and neck squamous cell carcinoma

Cancers

Volumn 3, Issue 1, 2011, Pages 747-772

  Walk, Elyse L ^a   Weed, Scott A ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Biomarker; Head and neck cancer; Invasion; Lymph node; Metastasis

Indexed keywords

CELL PROTEIN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; CORTACTIN; GELATINASE B; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MATRIX METALLOPROTEINASE 14; NIBRIN; PROTEIN CEP55; PROTEIN P53; S6 KINASE; SCATTER FACTOR RECEPTOR; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; SURVIVIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

APOPTOSIS; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CELL ADHESION; CELL CYCLE REGULATION; CELL MOTILITY; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HEAD AND NECK CARCINOMA; HUMAN; LYMPH NODE METASTASIS; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 79953699977     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3010747     Document Type: Review

References (158)

1. Leemans, C.R.; Tiwari, R.; Nauta, J.J.; van der Waal, I.; Snow, G.B. Regional Lymph Node Involvement and its Significance in the Development of Distant Metastases in Head and Neck Carcinoma. Cancer 1993, 71, 452-456.
2. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer Statistics, 2010. CA Cancer J. Clin. 2010, 60, 277-300.
3. Altekruse, S.F.; Kosary, C.L.; Krapcho, M.; Neyman, N.; Aminou, R.; Waldron, W.; Ruhl, J.; Howlader, N.; Tatalovich, Z.; Cho, H.; et al. SEER Cancer Statistics Review, 1975-2007; National Cancer Institute: Bethesda, MD, USA, 2010. Available online: http://seer.Cancer.gov/csr/1975_2007/ (Based on November 2009 SEER Data Submission, Posted to the SEER Web Site, 2010).
4. Pai, S.I.; Westra, W.H. Molecular Pathology of Head and Neck Cancer: Implications for Diagnosis, Prognosis, and Treatment. Annu. Rev. Pathol. 2009, 4, 49-70.
5. Le Tourneau, C.; Velten, M.; Jung, G.M.; Bronner, G.; Flesch, H.; Borel, C. Prognostic Indicators for Survival in Head and Neck Squamous Cell Carcinomas: Analysis of a Series of 621 Cases. Head Neck 2005, 27, 801-808.
6. Dunne, A.A.; Muller, H.H.; Eisele, D.W.; Kessel, K.; Moll, R.; Werner, J.A. Meta-Analysis of the Prognostic Significance of Perinodal Spread in Head and Neck Squamous Cell Carcinomas (HNSCC) Patients. Eur. J. Cancer 2006, 42, 1863-1868.
7. Liu, M.; Weynand, B.; Delos, M.; Marbaix, E. Prognostic Factors in Squamous Cell Carcinomas of the Head and Neck. Acta Otorhinolaryngol. Belg. 1999, 53, 155-160.
8. Hanahan, D.; Weinberg, R.A. The Hallmarks of Cancer. Cell 2000, 100, 57-70.
9. Cortesina, G.; Martone, T. Molecular Metastases Markers in Head and Neck Squamous Cell Carcinoma: Review of the Literature. Acta Otorhinolaryngol. Ital. 2006, 26, 317-325.
10. El-Naggar, A.K. Pathobiology of Head and Neck Squamous Tumorigenesis. Curr. Cancer Drug Targets 2007, 7, 606-612.
11. Takes, R.P.; Rinaldo, A.; Rodrigo, J.P.; Devaney, K.O.; Fagan, J.J.; Ferlito, A. Can Biomarkers Play a Role in the Decision about Treatment of the Clinically Negative Neck in Patients with Head and Neck Cancer? Head Neck 2008, 30, 525-538.
12. Molinolo, A.A.; Amornphimoltham, P.; Squarize, C.H.; Castilho, R.M.; Patel, V.; Gutkind, J.S. Dysregulated Molecular Networks in Head and Neck Carcinogenesis. Oral Oncol. 2009, 45, 324-334.
13. Thomas, G.R.; Nadiminti, H.; Regalado, J. Molecular Predictors of Clinical Outcome in Patients with Head and Neck Squamous Cell Carcinoma. Int. J. Exp. Pathol. 2005, 86, 347-363.
14. Hensen, E.F.; De Herdt, M.J.; Goeman, J.J.; Oosting, J.; Smit, V.T.; Cornelisse, C.J.; Baatenburg de Jong, R.J. Gene-Expression of Metastasized Versus Non-Metastasized Primary Head and Neck Squamous Cell Carcinomas: A Pathway-Based Analysis. BMC Cancer 2008, 8, 168.
15. Rickman, D.S.; Millon, R.; De Reynies, A.; Thomas, E.; Wasylyk, C.; Muller, D.; Abecassis, J.; Wasylyk, B. Prediction of Future Metastasis and Molecular Characterization of Head and Neck Squamous-Cell Carcinoma Based on Transcriptome and Genome Analysis by Microarrays. Oncogene 2008, 27, 6607-6622.
16. Roepman, P.; de Jager, A.; Groot Koerkamp, M.J.; Kummer, J.A.; Slootweg, P.J.; Holstege, F.C. Maintenance of Head and Neck Tumor Gene Expression Profiles upon Lymph Node Metastasis. Cancer Res. 2006, 66, 11110-11114.
17. Gentile, A.; Trusolino, L.; Comoglio, P.M. The Met Tyrosine Kinase Receptor in Development and Cancer. Cancer Metastasis Rev. 2008, 27, 85-94.
18. Comoglio, P.M.; Trusolino, L. Invasive Growth: From Development to Metastasis. J. Clin. Invest. 2002, 109, 857-862.
19. Benvenuti, S.; Comoglio, P.M. The MET Receptor Tyrosine Kinase in Invasion and Metastasis. J. Cell. Physiol. 2007, 213, 316-325.
20. Mueller, K.L.; Hunter, L.A.; Ethier, S.P.; Boerner, J.L. Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells. Cancer Res. 2008, 68, 3314-3322.
21. Sen, B.; Peng, S.H.; Saigal, B.; Williams, M.D.; Johnson, F.M. Distinct Interactions between c-Src and c-Met in Mediating Resistance to c-Src Inhibition in Head and Neck Cancer. Clin. Cancer Res. 2010, doi:10.1158/1078-0432.CCR-10-1617.
22. Egloff, A.M.; Grandis, J.R. Targeting Epidermal Growth Factor Receptor and SRC Pathways in Head and Neck Cancer. Semin. Oncol. 2008, 35, 286-297.
23. Kim, C.H.; Koh, Y.W.; Han, J.H.; Kim, J.W.; Lee, J.S.; Baek, S.J.; Hwang, H.S.; Choi, E.C. C-Met Expression as an Indicator of Survival Outcome in Patients with Oral Tongue Carcinoma. Head Neck 2010, 32, 1655-1664.
24. Kim, C.H.; Lee, J.S.; Kang, S.O.; Bae, J.H.; Hong, S.P.; Kahng, H. Serum Hepatocyte Growth Factor as a Marker of Tumor Activity in Head and Neck Squamous Cell Carcinoma. Oral Oncol. 2007, 43, 1021-1025.
25. Druzgal, C.H.; Chen, Z.; Yeh, N.T.; Thomas, G.R.; Ondrey, F.G.; Duffey, D.C.; Vilela, R.J.; Ende, K.; McCullagh, L.; Rudy, S.F. et al. A Pilot Study of Longitudinal Serum Cytokine and Angiogenesis Factor Levels as Markers of Therapeutic Response and Survival in Patients with Head and Neck Squamous Cell Carcinoma. Head Neck 2005, 27, 771-784.
26. Allen, C.; Duffy, S.; Teknos, T.; Islam, M.; Chen, Z.; Albert, P.S.; Wolf, G.; Van Waes, C. Nuclear Factor-kappaB-Related Serum Factors as Longitudinal Biomarkers of Response and Survival in Advanced Oropharyngeal Carcinoma. Clin. Cancer Res. 2007, 13, 3182-3190.
27. Kim, C.H.; Moon, S.K.; Bae, J.H.; Lee, J.H.; Han, J.H.; Kim, K.; Choi, E.C. Expression of Hepatocyte Growth Factor and c-Met in Hypopharyngeal Squamous Cell Carcinoma. Acta Otolaryngol. 2006, 126, 88-94.
28. Uchida, D.; Kawamata, H.; Omotehara, F.; Nakashiro, K.; Kimura-Yanagawa, T.; Hino, S.; Begum, N.M.; Hoque, M.O.; Yoshida, H.; Sato, M. et al. Role of HGF/c-Met System in Invasion and Metastasis of Oral Squamous Cell Carcinoma Cells in vitro and its Clinical Significance. Int. J. Cancer 2001, 93, 489-496.
29. Marshall, D.D.; Kornberg, L.J. Overexpression of Scatter Factor and its Receptor (c-Met) in Oral Squamous Cell Carcinoma. Laryngoscope 1998, 108, 1413-1417.
30. Galeazzi, E.; Olivero, M.; Gervasio, F.C.; De Stefani, A.; Valente, G.; Comoglio, P.M.; Di Renzo, M.F.; Cortesina, G. Detection of MET oncogene/hepatocyte Growth Factor Receptor in Lymph Node Metastases from Head and Neck Squamous Cell Carcinomas. Eur. Arch. Otorhinolaryngol. 1997, 254 (Suppl. 1), S138-S143.
31. Bishop, E.A.; Lengyel, E.R.; Yamada, S.D.; Montag, A.; Temkin, S.M. The Expression of Hepatocyte Growth Factor (HGF) and c-Met in Uterine Serous Carcinoma. Gynecol. Oncol. 2010, doi:doi:10.1016/j.ygyno.2010.11.031.
32. Zucali, P.A.; Ruiz, M.G.; Giovannetti, E.; Destro, A.; Varella-Garcia, M.; Floor, K.; Ceresoli, G.L.; Rodriguez, J.A.; Garassino, I.; Comoglio, P. et al. Role of cMET Expression in Non-Small-Cell Lung Cancer Patients Treated with EGFR Tyrosine Kinase Inhibitors. Ann. Oncol. 2008, 19, 1605-1612.
33. Mueller, K.L.; Yang, Z.Q.; Haddad, R.; Ethier, S.P.; Boerner, J.L. EGFR/Met Association Regulates EGFR TKI Resistance in Breast Cancer. J. Mol. Signal. 2010, 5, 8.
34. Liska, D.; Chen, C.T.; Bachleitner-Hofmann, T.; Christensen, J.G.; Weiser, M.R. HGF Rescues Colorectal Cancer Cells from EGFR Inhibition Via MET Activation. Clin. Cancer Res. 2010, 17, 472-482.
35. Kasahara, K.; Arao, T.; Sakai, K.; Matsumoto, K.; Sakai, A.; Kimura, H.; Sone, T.; Horiike, A.; Nishio, M.; Ohira, T. et al. Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Adenocarcinoma. Clin. Cancer Res. 2010, 16, 4616-4624.
36. Eder, J.P.; Vande Woude, G.F.; Boerner, S.A.; LoRusso, P.M. Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer. Clin. Cancer Res. 2009, 15, 2207-2214.
37. Fabbro, M.; Zhou, B.B.; Takahashi, M.; Sarcevic, B.; Lal, P.; Graham, M.E.; Gabrielli, B.G.; Robinson, P.J.; Nigg, E.A.; Ono, Y. et al. Cdk1/Erk2-and Plk1-Dependent Phosphorylation of a Centrosome Protein, Cep55, is Required for its Recruitment to Midbody and Cytokinesis. Dev. Cell. 2005, 9, 477-488.
38. Gemenetzidis, E.; Bose, A.; Riaz, A.M.; Chaplin, T.; Young, B.D.; Ali, M.; Sugden, D.; Thurlow, J.K.; Cheong, S.C.; Teo, S.H. et al. FOXM1 Upregulation is an Early Event in Human Squamous Cell Carcinoma and it is Enhanced by Nicotine during Malignant Transformation. PLoS One 2009, 4, e4849.
39. Chen, C.H.; Chien, C.Y.; Huang, C.C.; Hwang, C.F.; Chuang, H.C.; Fang, F.M.; Huang, H.Y.; Chen, C.M.; Liu, H.L.; Huang, C.Y. Expression of FLJ10540 is Correlated with Aggressiveness of Oral Cavity Squamous Cell Carcinoma by Stimulating Cell Migration and Invasion through Increased FOXM1 and MMP-2 Activity. Oncogene 2009, 28, 2723-2737.
40. Waseem, A.; Ali, M.; Odell, E.W.; Fortune, F.; Teh, M.T. Downstream Targets of FOXM1: CEP55 and HELLS are Cancer Progression Markers of Head and Neck Squamous Cell Carcinoma. Oral Oncol. 2010, 46, 536-542.
41. Antoccia, A.; Kobayashi, J.; Tauchi, H.; Matsuura, S.; Komatsu, K. Nijmegen Breakage Syndrome and Functions of the Responsible Protein, NBS1. Genome Dyn. 2006, 1, 191-205.
42. Lamarche, B.J.; Orazio, N.I.; Weitzman, M.D. The MRN Complex in Double-Strand Break Repair and Telomere Maintenance. FEBS Lett. 2010, 584, 3682-3695.
43. Hsu, D.S.; Chang, S.Y.; Liu, C.J.; Tzeng, C.H.; Wu, K.J.; Kao, J.Y.; Yang, M.H. Identification of Increased NBS1 Expression as a Prognostic Marker of Squamous Cell Carcinoma of the Oral Cavity. Cancer Sci. 2010, 101, 1029-1037.
44. Yang, M.H.; Chiang, W.C.; Chou, T.Y.; Chang, S.Y.; Chen, P.M.; Teng, S.C.; Wu, K.J. Increased NBS1 Expression is a Marker of Aggressive Head and Neck Cancer and Overexpression of NBS1 Contributes to Transformation. Clin. Cancer Res. 2006, 12, 507-515.
45. Yang, M.H.; Chang, S.Y.; Chiou, S.H.; Liu, C.J.; Chi, C.W.; Chen, P.M.; Teng, S.C.; Wu, K.J. Overexpression of NBS1 Induces Epithelial-Mesenchymal Transition and Co-Expression of NBS1 and Snail Predicts Metastasis of Head and Neck Cancer. Oncogene 2007, 26, 1459-1467.
46. Park, S.L.; Bastani, D.; Goldstein, B.Y.; Chang, S.C.; Cozen, W.; Cai, L.; Cordon-Cardo, C.; Ding, B.; Greenland, S.; He, N. et al. Associations between NBS1 Polymorphisms, Haplotypes and Smoking-Related Cancers. Carcinogenesis 2010, 31, 1264-1271.
47. Schuetz, J.M.; MaCarthur, A.C.; Leach, S.; Lai, A.S.; Gallagher, R.P.; Connors, J.M.; Gascoyne, R.D.; Spinelli, J.J.; Brooks-Wilson, A.R. Genetic Variation in the NBS1, MRE1 1, RAD50 and BLM Genes and Susceptibility to Non-Hodgkin Lymphoma. BMC Med. Genet. 2009, 10, 117.
48. di Masi, A.; Antoccia, A. NBS1 Heterozygosity and Cancer Risk. Curr. Genomics 2008, 9, 275-281.
49. Duffy, M.J.; O'Donovan, N.; Brennan, D.J.; Gallagher, W.M.; Ryan, B.M. Survivin: A Promising Tumor Biomarker. Cancer Lett. 2007, 249, 49-60.
50. Guha, M.; Altieri, D.C. Survivin as a Global Target of Intrinsic Tumor Suppression Networks. Cell Cycle 2009, 8, 2708-2710.
51. Kim, Y.H.; Kim, S.M.; Kim, Y.K.; Hong, S.P.; Kim, M.J.; Myoung, H. Evaluation of Survivin as a Prognostic Marker in Oral Squamous Cell Carcinoma. J. Oral Pathol. Med. 2010, 39, 368-375.
52. Khan, Z.; Tiwari, R.P.; Mulherkar, R.; Sah, N.K.; Prasad, G.B.; Shrivastava, B.R.; Bisen, P.S. Detection of Survivin and p53 in Human Oral Cancer: Correlation with Clinicopathologic Findings. Head Neck 2009, 31, 1039-1048.
53. Lippert, B.M.; Knauer, S.K.; Fetz, V.; Mann, W.; Stauber, R.H. Dynamic Survivin in Head and Neck Cancer: Molecular Mechanism and Therapeutic Potential. Int. J. Cancer 2007, 121, 1169-1174.
54. Qi, G.; Kudo, Y.; Ando, T.; Tsunematsu, T.; Shimizu, N.; Siriwardena, S.B.; Yoshida, M.; Keikhaee, M.R.; Ogawa, I.; Takata, T. Nuclear Survivin Expression is Correlated with Malignant Behaviors of Head and Neck Cancer Together with Aurora-B. Oral Oncol. 2010, 46, 263-270.
55. Lin, J.; Guan, Z.; Wang, C.; Feng, L.; Zheng, Y.; Caicedo, E.; Bearth, E.; Peng, J.R.; Gaffney, P.; Ondrey, F.G. Inhibitor of Differentiation 1 Contributes to Head and Neck Squamous Cell Carcinoma Survival Via the NF-kappaB/survivin and Phosphoinositide 3-kinase/Akt Signaling Pathways. Clin. Cancer Res. 2010, 16, 77-87.
56. Preuss, S.F.; Weinell, A.; Molitor, M.; Semrau, R.; Stenner, M.; Drebber, U.; Wedemeyer, I.; Hoffmann, T.K.; Guntinas-Lichius, O.; Klussmann, J.P. Survivin and Epidermal Growth Factor Receptor Expression in Surgically Treated Oropharyngeal Squamous Cell Carcinoma. Head Neck 2008b, 30, 1318-1324.
57. Preuss, S.F.; Weinell, A.; Molitor, M.; Stenner, M.; Semrau, R.; Drebber, U.; Weissenborn, S.J.; Speel, E.J.; Wittekindt, C.; Guntinas-Lichius, O. et al. Nuclear Survivin Expression is Associated with HPV-Independent Carcinogenesis and is an Indicator of Poor Prognosis in Oropharyngeal Cancer. Br. J. Cancer 2008a, 98, 627-632.
58. Fetz, V.; Bier, C.; Habtemichael, N.; Schuon, R.; Schweitzer, A.; Kunkel, M.; Engels, K.; Kovacs, A.F.; Schneider, S.; Mann, W. et al. Inducible NO Synthase Confers Chemoresistance in Head and Neck Cancer by Modulating Survivin. Int. J. Cancer 2009, 124, 2033-2041.
59. Wang, S.; Huang, X.; Lee, C.K.; Liu, B. Elevated Expression of erbB3 Confers Paclitaxel Resistance in erbB2-Overexpressing Breast Cancer Cells Via Upregulation of Survivin. Oncogene 2010, 29, 4225-4236.
60. Promkan, M.; Liu, G.; Patmasiriwat, P.; Chakrabarty, S. BRCA1 Modulates Malignant Cell Behavior, the Expression of Survivin and Chemosensitivity in Human Breast Cancer Cells. Int. J. Cancer 2009, 125, 2820-2828.
61. Wang, Q.; Wu, P.C.; Roberson, R.S.; Luk, B.V.; Ivanova, I.; Chu, E.; Wu, D.Y. Survivin and Escaping in Therapy-Induced Cellular Senescence. Int. J. Cancer 2010, doi:10.1002/ijc.25482.
62. Su, L.; Wang, Y.; Xiao, M.; Lin, Y.; Yu, L. Up-Regulation of Survivin in Oral Squamous Cell Carcinoma Correlates with Poor Prognosis and Chemoresistance. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2010, 110, 484-491.
63. Carriere, A.; Ray, H.; Blenis, J.; Roux, P.P. The RSK Factors of Activating the Ras/MAPK Signaling Cascade. Front. Biosci. 2008, 13, 4258-4275.
64. Anjum, R.; Blenis, J. The RSK Family of Kinases: Emerging Roles in Cellular Signalling. Nat. Rev. Mol. Cell Biol. 2008, 9, 747-758.
65. Kang, S.; Elf, S.; Lythgoe, K.; Hitosugi, T.; Taunton, J.; Zhou, W.; Xiong, L.; Wang, D.; Muller, S.; Fan, S. et al. P90 Ribosomal S6 Kinase 2 Promotes Invasion and Metastasis of Human Head and Neck Squamous Cell Carcinoma Cells. J. Clin. Invest. 2010, 120, 1165-1177.
66. Cho, Y.Y.; Yao, K.; Kim, H.G.; Kang, B.S.; Zheng, D.; Bode, A.M.; Dong, Z. Ribosomal S6 Kinase 2 is a Key Regulator in Tumor Promoter Induced Cell Transformation. Cancer Res. 2007, 67, 8104-8112.
67. Nguyen, T.L. Targeting RSK: An Overview of Small Molecule Inhibitors. Anticancer Agents Med. Chem. 2008, 8, 710-716.
68. Ammer, A.G.; Weed, S.A. Cortactin Branches Out: Roles in Regulating Protrusive Actin Dynamics. Cell Motil. Cytoskeleton 2008, 65, 687-707.
69. Rodrigo, J.P.; Garcia, L.A.; Ramos, S.; Lazo, P.S.; Suarez, C. EMS1 Gene Amplification Correlates with Poor Prognosis in Squamous Cell Carcinomas of the Head and Neck. Clin. Cancer Res. 2000, 6, 3177-3182.
70. Rothschild, B.L.; Shim, A.H.; Ammer, A.G.; Kelley, L.C.; Irby, K.B.; Head, J.A.; Chen, L.; Varella-Garcia, M.; Sacks, P.G.; Frederick, B. et al. Cortactin Overexpression Regulates Actin-Related Protein 2/3 Complex Activity, Motility, and Invasion in Carcinomas with Chromosome 1 1q13 Amplification. Cancer Res. 2006, 66, 8017-8025.
71. Meredith, S.D.; Levine, P.A.; Burns, J.A.; Gaffey, M.J.; Boyd, J.C.; Weiss, L.M.; Erickson, N.L.; Williams, M.E. Chromosome 11q13 Amplification in Head and Neck Squamous Cell Carcinoma. Association with Poor Prognosis. Arch. Otolaryngol. Head. Neck. Surg. 1995, 121, 790-794.
72. Williams, M.E.; Gaffey, M.J.; Weiss, L.M.; Wilczynski, S.P.; Schuuring, E.; Levine, P.A. Chromosome 11Q13 Amplification in Head and Neck Squamous Cell Carcinoma. Arch. Otolaryngol. Head. Neck. Surg. 1993, 119, 1238-1243.
73. Luo, M.L.; Shen, X.M.; Zhang, Y.; Wei, F.; Xu, X.; Cai, Y.; Zhang, X.; Sun, Y.T.; Zhan, Q.M.; Wu, M. et al. Amplification and Overexpression of CTTN (EMS 1) Contribute to the Metastasis of Esophageal Squamous Cell Carcinoma by Promoting Cell Migration and Anoikis Resistance. Cancer Res. 2006, 66, 11690-11699.
74. Yamada, S.I.; Yanamoto, S.; Kawasaki, G.; Mizuno, A.; Nemoto, T.K. Overexpression of Cortactin Increases Invasion Potential in Oral Squamous Cell Carcinoma. Pathol. Oncol. Res. 2010, 4, 523-531.
75. Rodrigo, J.P.; Garcia-Carracedo, D.; Garcia, L.A.; Menendez, S.; Allonca, E.; Gonzalez, M.V.; Fresno, M.F.; Suarez, C.; Garcia-Pedrero, J.M. Distinctive Clinicopathological Associations of Amplification of the Cortactin Gene at 1 1q13 in Head and Neck Squamous Cell Carcinomas. J. Pathol. 2009, 217, 516-523.
76. Hofman, P.; Butori, C.; Havet, K.; Hofman, V.; Selva, E.; Guevara, N.; Santini, J.; Van Obberghen-Schilling, E. Prognostic Significance of Cortactin Levels in Head and Neck Squamous Cell Carcinoma: Comparison with Epidermal Growth Factor Receptor Status. Br. J. Cancer 2008, 98, 956-964.
77. Timpson, P.; Wilson, A.S.; Lehrbach, G.M.; Sutherland, R.L.; Musgrove, E.A.; Daly, R.J. Aberrant Expression of Cortactin in Head and Neck Squamous Cell Carcinoma Cells is Associated with Enhanced Cell Proliferation and Resistance to the Epidermal Growth Factor Receptor Inhibitor Gefitinib. Cancer Res. 2007, 67, 9304-9314.
78. Fantozzi, I.; Grall, D.; Cagnol, S.; Stanchi, F.; Sudaka, A.; Brunstein, M.C.; Bozec, A.; Fischel, J.L.; Milano, G.; Van Obberghen-Schilling, E. Overexpression of Cortactin in Head and Neck Squamous Cell Carcinomas can be Uncoupled from Augmented EGF Receptor Expression. Acta Oncol. 2008, 47, 1502-1512.
79. Gibcus, J.H.; Mastik, M.F.; Menkema, L.; de Bock, G.H.; Kluin, P.M.; Schuuring, E.; van der Wal, J.E. Cortactin Expression Predicts Poor Survival in Laryngeal Carcinoma. Br. J. Cancer 2008, 98, 950-955.
80. Orian-Rousseau, V. CD44, a Therapeutic Target for Metastasising Tumours. Eur. J. Cancer 2010, 46, 1271-1277.
81. Wang, S.J.; Wong, G.; de Heer, A.M.; Xia, W.; Bourguignon, L.Y. CD44 Variant Isoforms in Head and Neck Squamous Cell Carcinoma Progression. Laryngoscope 2009, 119, 1518-1530.
82. Yuce, I.; Bayram, A.; Cagli, S.; Canoz, O.; Bayram, S.; Guney, E. The Role of CD44 and Matrix Metalloproteinase-9 Expression in Predicting Neck Metastasis of Supraglottic Laryngeal Carcinoma. Am. J. Otolaryngol. 2010, doi:10.1016/j.amjoto.2010.01.001.
83. Lin, J.T.; Chang, T.H.; Chang, C.S.; Wang, W.H.; Su, B.W.; Lee, K.D.; Chang, P.J. Prognostic Value of Pretreatment CD44 mRNA in Peripheral Blood of Patients with Locally Advanced Head and Neck Cancer. Oral Oncol. 2010, 46, e29-e33.
84. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell 2010, 141, 52-67.
85. Yu, Q.; Stamenkovic, I. Cell Surface-Localized Matrix Metalloproteinase-9 Proteolytically Activates TGF-B eta and Promotes Tumor Invasion and Angiogenesis. Genes Dev. 2000, 14, 163-176.
86. Lee, J.I.; Jin, B.H.; Kim, M.A.; Yoon, H.J.; Hong, S.P.; Hong, S.D. Prognostic Significance of CXCR-4 Expression in Oral Squamous Cell Carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2009, 107, 678-684.
87. Sterz, C.M.; Kulle, C.; Dakic, B.; Makarova, G.; Bottcher, M.C.; Bette, M.; Werner, J.A.; Mandic, R. A Basal-Cell-Like Compartment in Head and Neck Squamous Cell Carcinomas Represents the Invasive Front of the Tumor and is Expressing MMP-9. Oral Oncol. 2010, 46, 116-122.
88. Liu, C.J.; Chang, K.W.; Lin, S.C.; Cheng, H.W. Presurgical Serum Levels of Matrix Metalloproteinase-9 and Vascular Endothelial Growth Factor in Oral Squamous Cell Carcinoma. Oral Oncol. 2009, 45, 920-925.
89. Ruokolainen, H.; Paakko, P.; Turpeenniemi-Hujanen, T. Serum Matrix Metalloproteinase-9 in Head and Neck Squamous Cell Carcinoma is a Prognostic Marker. Int. J. Cancer 2005, 116, 422-427.
90. Zhang, H.; Liu, M.; Sun, Y.; Lu, J. MMP-14 can Serve as a Prognostic Marker in Patients with Supraglottic Cancer. Eur. Arch. Otorhinolaryngol. 2009, 266, 1427-1434.
91. Clark, E.S.; Whigham, A.S.; Yarbrough, W.G.; Weaver, A.M. Cortactin is an Essential Regulator of Matrix Metalloproteinase Secretion and Extracellular Matrix Degradation in Invadopodia. Cancer Res. 2007, 67, 4227-4235.
92. Clark, E.S.; Weaver, A.M. A New Role for Cortactin in Invadopodia: Regulation of Protease Secretion. Eur. J. Cell Biol. 2008, 87, 581-590.
93. Coussens, L.M.; Fingleton, B.; Matrisian, L.M. Matrix Metalloproteinase Inhibitors and Cancer: Trials and Tribulations. Science 2002, 295, 2387-2392.
94. Dorman, G.; Cseh, S.; Hajdu, I.; Barna, L.; Konya, D.; Kupai, K.; Kovacs, L.; Ferdinandy, P. Matrix Metalloproteinase Inhibitors: A Critical Appraisal of Design Principles and Proposed Therapeutic Utility. Drugs 2010, 70, 949-964.
95. Kakinuma, T.; Hwang, S.T. Chemokines, Chemokine Receptors, and Cancer Metastasis. J. Leukoc. Biol. 2006, 79, 639-651.
96. Ben-Baruch, A. Site-Specific Metastasis Formation: Chemokines as Regulators of Tumor Cell Adhesion, Motility and Invasion. Cell. Adh Migr. 2009, 3, 328-333.
97. Teicher, B.A.; Fricker, S.P. CXCL12 (SDF-1)/CXCR4 Pathway in Cancer. Clin. Cancer Res. 2010, 16, 2927-2931.
98. Tan, C.T.; Chu, C.Y.; Lu, Y.C.; Chang, C.C.; Lin, B.R.; Wu, H.H.; Liu, H.L.; Cha, S.T.; Prakash, E.; Ko, J.Y. et al. CXCL12/CXCR4 Promotes Laryngeal and Hypopharyngeal Squamous Cell Carcinoma Metastasis through MMP-13-Dependent Invasion Via the ERK1/2/AP-1 Pathway. Carcinogenesis 2008, 29, 1519-1527.
99. Meng, X.; Wuyi, L.; Yuhong, X.; Xinming, C. Expression of CXCR4 in Oral Squamous Cell Carcinoma: Correlations with Clinicopathology and Pivotal Role of Proliferation. J. Oral Pathol. Med. 2010, 39, 63-68.
100. Ueda, M.; Shimada, T.; Goto, Y.; Tei, K.; Nakai, S.; Hisa, Y.; Kannagi, R. Expression of CC-Chemokine Receptor 7 (CCR7) and CXC-Chemokine Receptor 4 (CXCR4) in Head and Neck Squamous Cell Carcinoma. Auris Nasus Larynx 2010, 37, 488-495.
101. Ou, D.L.; Chien, H.F.; Chen, C.L.; Lin, T.C.; Lin, L.I. Role of Twist in Head and Neck Carcinoma with Lymph Node Metastasis. Anticancer Res. 2008, 28, 1355-1359.
102. Pitkin, L.; Luangdilok, S.; Corbishley, C.; Wilson, P.O.; Dalton, P.; Bray, D.; Mady, S.; Williamson, P.; Odutoye, T.; Rhys Evans, P. et al. Expression of CC Chemokine Receptor 7 in Tonsillar Cancer Predicts Cervical Nodal Metastasis, Systemic Relapse and Survival. Br. J. Cancer 2007, 97, 670-677.
103. Shang, Z.J.; Liu, K.; Shao, Z. Expression of Chemokine Receptor CCR7 is Associated with Cervical Lymph Node Metastasis of Oral Squamous Cell Carcinoma. Oral Oncol. 2009, 45, 480-485.
104. Wang, J.; Seethala, R.R.; Zhang, Q.; Gooding, W.; van Waes, C.; Hasegawa, H.; Ferris, R.L. Autocrine and Paracrine Chemokine Receptor 7 Activation in Head and Neck Cancer: Implications for Therapy. J. Natl. Cancer Inst. 2008, 100, 502-512.
105. Wolf, M.; Albrecht, S.; Marki, C. Proteolytic Processing of Chemokines: Implications in Physiological and Pathological Conditions. Int. J. Biochem. Cell Biol. 2008, 40, 1185-1198.
106. Yu, T.; Wu, Y.; Helman, J.I.; Wen, Y.; Wang, C.; Li, L. CXCR4 Promotes Oral Squamous Cell Carcinoma Migration and Invasion through Inducing Expression of MMP-9, 13 Via the ERK Signaling Pathway. Mol. Cancer. Res. 2011, doi:10.1158/1541-7786.MCR-10-0386.
107. Raman, D.; Baugher, P.J.; Thu, Y.M.; Richmond, A. Role of Chemokines in Tumor Growth. Cancer Lett. 2007, 256, 137-165.
108. Wang, J.; Xi, L.; Hunt, J.L.; Gooding, W.; Whiteside, T.L.; Chen, Z.; Godfrey, T.E.; Ferris, R.L. Expression Pattern of Chemokine Receptor 6 (CCR6) and CCR7 in Squamous Cell Carcinoma of the Head and Neck Identifies a Novel Metastatic Phenotype. Cancer Res. 2004, 64, 1861-1866.
109. Margaritescu, C.; Pirici, D.; Simionescu, C.; Mogoanta, L.; Raica, M.; Stinga, A.; Ciurea, R.; Stepan, A.; Stinga, A.; Ribatti, D. VEGF and VEGFRs Expression in Oral Squamous Cell Carcinoma. Rom. J. Morphol. Embryol. 2009, 50, 527-548.
110. Joo, Y.H.; Jung, C.K.; Kim, M.S.; Sun, D.I. Relationship between Vascular Endothelial Growth Factor and Notch 1 Expression and Lymphatic Metastasis in Tongue Cancer. Otolaryngol. Head. Neck. Surg. 2009, 140, 512-518.
111. Hicklin, D.J.; Ellis, L.M. Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis. J. Clin. Oncol. 2005, 23, 1011-1027.
112. Winder, T.; Lenz, H.J. Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer. Gastroenterology 2010, 138, 2163-2176.
113. Guo, S.; Colbert, L.S.; Fuller, M.; Zhang, Y.; Gonzalez-Perez, R.R. Vascular Endothelial Growth Factor Receptor-2 in Breast Cancer. Biochim. Biophys. Acta 2010, 1806, 108-121.
114. Delli Carpini, J.; Karam, A.K.; Montgomery, L. Vascular Endothelial Growth Factor and its Relationship to the Prognosis and Treatment of Breast, Ovarian, and Cervical Cancer. Angiogenesis 2010, 13, 43-58.
115. Hong, D.Y.; Lee, B.J.; Lee, J.C.; Choi, J.S.; Wang, S.G.; Ro, J.H. Expression of VEGF, HGF, IL-6, IL-8, MMP-9, Telomerase in Peripheral Blood of Patients with Head and Neck Squamous Cell Carcinoma. Clin. Exp. Otorhinolaryngol. 2009, 2, 186-192.
116. Lv, X.; Xiang, Y.Q.; Cao, S.M.; Qian, C.N.; Li, N.W.; Guo, L.; Mai, H.Q.; Chen, Q.Y.; Huang, P.Y.; Luo, D. et al. Prospective Validation of the Prognostic Value of Elevated Serum Vascular Endothelial Growth Factor in Patients with Nasopharyngeal Carcinoma: More Distant Metastases and Shorter overall Survival After Treatment. Head Neck 2010, doi:10.1002/hed.21541.
117. Sugiura, T.; Inoue, Y.; Matsuki, R.; Ishii, K.; Takahashi, M.; Abe, M.; Shirasuna, K. VEGF-C and VEGF-D Expression is Correlated with Lymphatic Vessel Density and Lymph Node Metastasis in Oral Squamous Cell Carcinoma: Implications for use as a Prognostic Marker. Int. J. Oncol. 2009, 34, 673-680.
118. Borggrefe, T.; Oswald, F. The Notch Signaling Pathway: Transcriptional Regulation at Notch Target Genes. Cell Mol. Life Sci. 2009, 66, 1631-1646.
119. Shao, Z.; Zhang, W.F.; Chen, X.M.; Shang, Z.J. Expression of EphA2 and VEGF in Squamous Cell Carcinoma of the Tongue: Correlation with the Angiogenesis and Clinical Outcome. Oral Oncol. 2008, 44, 1110-1117.
120. Pentheroudakis, G.; Angouridakis, N.; Wirtz, R.; Nikolaou, A.; Kalogeras, K.T.; Pavlidis, N.; Fountzilas, G. Transcriptional Activity of Human Epidermal Growth Factor Receptor Family and Angiogenesis Effectors in Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma and Correlation with Patient Outcome. J. Oncol. 2009, 2009, 854127.
121. Rueda, A.; Cazorla, O.; Perez, L.; Alvarez, M.; Redondo, M.; Gallego, E.; Saez, M.; Medina, J.A.; Solano, J.; Matilla, A. Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Tumor Expression in Patients with Advanced Laryngeal Cancer After Induction Chemotherapy for Organ Preservation. Head Neck 2010, doi:10.1002/hed.21551.
122. Faustino, S.E.; Oliveira, D.T.; Nonogaki, S.; Landman, G.; Carvalho, A.L.; Kowalski, L.P. Expression of Vascular Endothelial Growth Factor-C does Not Predict Occult Lymph-Node Metastasis in Early Oral Squamous Cell Carcinoma. Int. J. Oral Maxillofac. Surg. 2008, 37, 372-378.
123. Luqman, S.; Pezzuto, J.M. NFkappaB: A Promising Target for Natural Products in Cancer Chemoprevention. Phytother. Res. 2010, 24, 949-963.
124. Aggarwal, B.B. Nuclear Factor-kappaB: The Enemy within Cancer. Cell 2004, 6, 203-208.
125. Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-Related Inflammation. Nature 2008, 454, 436-444.
126. Yan, M.; Xu, Q.; Zhang, P.; Zhou, X.J.; Zhang, Z.Y.; Chen, W.T. Correlation of NF-kappaB Signal Pathway with Tumor Metastasis of Human Head and Neck Squamous Cell Carcinoma. BMC Cancer 2010, 10, 437.
127. Huang, C.; Huang, K.; Wang, C.; Jiang, Z.D.; Li, X.X.; Wang, H.P.; Chen, H.Y. Overexpression of Mitogen-Activated Protein Kinase Kinase 4 and Nuclear Factor-kappaB in Laryngeal Squamous Cell Carcinoma: A Potential Indicator for Poor Prognosis. Oncol. Rep. 2009, 22, 89-95.
128. Yoshida, K.; Sasaki, R.; Nishimura, H.; Okamoto, Y.; Suzuki, Y.; Kawabe, T.; Saito, M.; Otsuki, N.; Hayashi, Y.; Soejima, T. et al. Nuclear Factor-kappaB Expression as a Novel Marker of Radioresistance in Early-Stage Laryngeal Cancer. Head Neck 2010, 32, 646-655.
129. Pham, C.G.; Bubici, C.; Zazzeroni, F.; Knabb, J.R.; Papa, S.; Kuntzen, C.; Franzoso, G. Upregulation of Twist-1 by NF-kappaB Blocks Cytotoxicity Induced by Chemotherapeutic Drugs. Mol. Cell. Biol. 2007, 27, 3920-3935.
130. Julien, S.; Puig, I.; Caretti, E.; Bonaventure, J.; Nelles, L.; van Roy, F.; Dargemont, C.; de Herreros, A.G.; Bellacosa, A.; Larue, L. Activation of NF-kappaB by Akt Upregulates Snail Expression and Induces Epithelium Mesenchyme Transition. Oncogene 2007, 26, 7445-7456.
131. Rehman, A.O.; Wang, C.Y. SDF-1alpha Promotes Invasion of Head and Neck Squamous Cell Carcinoma by Activating NF-kappaB. J. Biol. Chem. 2008, 283, 19888-19894.
132. Chaturvedi, M.M.; Sung, B.; Yadav, V.R.; Kannappan, R.; Aggarwal, B.B. NF-kappaB Addiction and its Role in Cancer: 'One Size does Not Fit all'. Oncogene 2010, doi:10.1038/onc.2010.566.
133. Liu, F.Y.; Zhao, Z.J.; Li, P.; Ding, X.; Guo, N.; Yang, L.L.; Zong, Z.H.; Sun, C.F. NF-kappaB Participates in Chemokine Receptor 7-Mediated Cell Survival in Metastatic Squamous Cell Carcinoma of the Head and Neck. Oncol. Rep. 2011, 25, 383-391.
134. Iwatsuki, M.; Mimori, K.; Yokobori, T.; Ishi, H.; Beppu, T.; Nakamori, S.; Baba, H.; Mori, M. Epithelial-Mesenchymal Transition in Cancer Development and its Clinical Significance. Cancer Sci. 2010, 101, 293-299.
135. Yilmaz, M.; Christofori, G. EMT, the Cytoskeleton, and Cancer Cell Invasion. Cancer Metastasis Rev. 2009, 28, 15-33.
136. Ouyang, G.; Wang, Z.; Fang, X.; Liu, J.; Yang, C.J. Molecular Signaling of the Epithelial to Mesenchymal Transition in Generating and Maintaining Cancer Stem Cells. Cell Mol. Life Sci. 2010, 67, 2605-2618.
137. Yang, J.; Mani, S.A.; Donaher, J.L.; Ramaswamy, S.; Itzykson, R.A.; Come, C.; Savagner, P.; Gitelman, I.; Richardson, A.; Weinberg, R.A. Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis. Cell 2004, 117, 927-939.
138. Yang, M.H.; Wu, M.Z.; Chiou, S.H.; Chen, P.M.; Chang, S.Y.; Liu, C.J.; Teng, S.C.; Wu, K.J. Direct Regulation of TWIST by HIF-1alpha Promotes Metastasis. Nat. Cell Biol. 2008, 10, 295-305.
139. Yang, M.H.; Hsu, D.S.; Wang, H.W.; Wang, H.J.; Lan, H.Y.; Yang, W.H.; Huang, C.H.; Kao, S.Y.; Tzeng, C.H.; Tai, S.K. et al. Bmi1 is Essential in Twist1-Induced Epithelial-Mesenchymal Transition. Nat. Cell Biol. 2010, 12, 982-992.
140. Shiota, M.; Izumi, H.; Onitsuka, T.; Miyamoto, N.; Kashiwagi, E.; Kidani, A.; Yokomizo, A.; Naito, S.; Kohno, K. Twist Promotes Tumor Cell Growth through YB-1 Expression. Cancer Res. 2008, 68, 98-105.
141. Yu, C.C.; Lo, W.L.; Chen, Y.W.; Huang, P.I.; Hsu, H.S.; Tseng, L.M.; Hung, S.C.; Kao, S.Y.; Chang, C.J.; Chiou, S.H. Bmi-1 Regulates Snail Expression and Promotes Metastasis Ability in Head and Neck Squamous Cancer-Derived ALDH1 Positive Cells. J. Oncol. 2011, 2011, doi:10.1155/2011/609259.
142. Hayry, V.; Makinen, L.K.; Atula, T.; Sariola, H.; Makitie, A.; Leivo, I.; Keski-Santti, H.; Lundin, J.; Haglund, C.; Hagstrom, J. Bmi-1 Expression Predicts Prognosis in Squamous Cell Carcinoma of the Tongue. Br. J. Cancer 2010, 102, 892-897.
143. Hsu, D.S.; Lan, H.Y.; Huang, C.H.; Tai, S.K.; Chang, S.Y.; Tsai, T.L.; Chang, C.C.; Tzeng, C.H.; Wu, K.J.; Kao, J.Y. et al. Regulation of Excision Repair Cross-Complementation Group 1 by Snail Contributes to Cisplatin Resistance in Head and Neck Cancer. Clin. Cancer Res. 2010, 16, 4561-4571.
144. Semenza, G.L. Defining the Role of Hypoxia-Inducible Factor 1 in Cancer Biology and Therapeutics. Oncogene 2010, 29, 625-634.
145. Mizukami, Y.; Kohgo, Y.; Chung, D.C. Hypoxia Inducible Factor-1 Independent Pathways in Tumor Angiogenesis. Clin. Cancer Res. 2007, 13, 5670-5674.
146. Uehara, M.; Sano, K.; Ikeda, H.; Nonaka, M.; Asahina, I. Hypoxia-Inducible Factor 1 Alpha in Oral Squamous Cell Carcinoma and its Relation to Prognosis. Oral Oncol. 2009, 45, 241-246.
147. Gort, E.H.; Groot, A.J.; van der Wall, E.; van Diest, P.J.; Vooijs, M.A. Hypoxic Regulation of Metastasis Via Hypoxia-Inducible Factors. Curr. Mol. Med. 2008, 8, 60-67.
148. Yang, M.H.; Wu, K.J. TWIST Activation by Hypoxia Inducible Factor-1 (HIF-1): Implications in Metastasis and Development. Cell Cycle 2008, 7, 2090-2096.
149. Rapisarda, A.; Melillo, G. Role of the Hypoxic Tumor Microenvironment in the Resistance to Anti-Angiogenic Therapies. Drug Resist. Updat. 2009, 12, 74-80.
150. Goon, P.K.; Stanley, M.A.; Ebmeyer, J.; Steinstrasser, L.; Upile, T.; Jerjes, W.; Bernal-Sprekelsen, M.; Gorner, M.; Sudhoff, H.H. HPV & Head and Neck Cancer: A Descriptive Update. Head Neck Oncol. 2009, 1, 36.
151. Chung, C.H.; Gillison, M.L. Human Papillomavirus in Head and Neck Cancer: Its Role in Pathogenesis and Clinical Implications. Clin. Cancer Res. 2009, 15, 6758-6762.
152. Abbas, T.; Dutta, A. P21 in Cancer: Intricate Networks and Multiple Activities. Nat. Rev. Cancer. 2009, 9, 400-414.
153. Roninson, I.B. Oncogenic Functions of Tumour Suppressor p21(Waf1/Cip1/Sdi1): Association with Cell Senescence and Tumour-Promoting Activities of Stromal Fibroblasts. Cancer Lett. 2002, 179, 1-14.
154. Fischer, C.A.; Jung, M.; Zlobec, I.; Green, E.; Storck, C.; Tornillo, L.; Lugli, A.; Wolfensberger, M.; Terracciano, L.M. Co-Overexpression of p21 and Ki-67 in Head and Neck Squamous Cell Carcinoma Relative to a significantly Poor Prognosis. Head Neck 2010, 33, 267-273.
155. Hafkamp, H.C.; Mooren, J.J.; Claessen, S.M.; Klingenberg, B.; Voogd, A.C.; Bot, F.J.; Klussmann, J.P.; Hopman, A.H.; Manni, J.J.; Kremer, B. et al. P21 Cip1/WAF1 Expression is Strongly Associated with HPV-Positive Tonsillar Carcinoma and a Favorable Prognosis. Mod. Pathol. 2009, 22, 686-698.
156. Maxwell, J.H.; Kumar, B.; Feng, F.Y.; Worden, F.P.; Lee, J.S.; Eisbruch, A.; Wolf, G.T.; Prince, M.E.; Moyer, J.S.; Teknos, T.N. et al. Tobacco use in Human Papillomavirus-Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor Recurrence. Clin. Cancer Res. 2010, 16, 1226-1235.
157. McDermott, U.; Downing, J.R.; Stratton, M.R. Genomics and the Continuum of Cancer Care. N. Engl. J. Med. 2011, 364, 340-350.
158. Saintigny, P.; Zhang, L.; Fan, Y.H.; El-Naggar, A.K.; Papadimitrakopoulou, V.A.; Feng, L.; Lee, J.J.; Kim, E.S.; Hong, W.K.; Mao, L. Gene Expression Profiling Predicts the Development of Oral Cancer. Cancer Prev. Res. 2011, 4, 218.